Home LiteratureArticle Details
PMID: 3164989 Published · ppublish English Comparative Study Journal Article

Ciprofloxacin therapy of experimental endocarditis caused by methicillin-susceptible or methicillin-resistant Staphylococcus aureus.

Antimicrobial agents and chemotherapy ·Vol. 32 ·No. 5 ·1988-05-00 ·Pages 747-51

Fernandez-Guerrero M, Rouse M, Henry N, Wilson W

Abstract

Ciprofloxacin was more effective (P less than 0.01) than either imipenem or nafcillin therapy of experimental methicillin-susceptible Staphylococcus aureus endocarditis in rabbits after 2 or 3 days of treatment. There was no significant difference between results of treatment of methicillin-susceptible S. aureus experimental endocarditis with ciprofloxacin and results with the combination of nafcillin and gentamicin. Ciprofloxacin was more effective (P less than 0.01) than vancomycin therapy of experimental methicillin-resistant S. aureus endocarditis after 3 days of treatment. After 5 days of treatment, there was no significant difference between the results of treatment of experimental methicillin-resistant S. aureus endocarditis with ciprofloxacin and results with vancomycin.

MeSH Terms
Animals Ciprofloxacin/therapeutic use Drug Therapy, Combination Endocarditis, Bacterial/drug therapy Gentamicins/therapeutic use Humans Imipenem Methicillin/pharmacology Nafcillin/therapeutic use Penicillin Resistance Rabbits Staphylococcal Infections/drug therapy Staphylococcus aureus/drug effects Thienamycins/therapeutic use Vancomycin/therapeutic use
Chemicals
Gentamicins Thienamycins Nafcillin Ciprofloxacin Vancomycin Imipenem Methicillin
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Fernandez-Guerrero M
Fundacion Jimenez Diaz, Madrid, Spain.
Rouse M
Henry N
Wilson W
References (20)
20 references, click to expand
  1. Experimental endocarditis I. Staphylococcal endocarditis in rabbits resulting from placement of a polyethylene catheter in the right side of the heart.
    Yale J Biol Med. 1970 Jun;42(6):394-410 PMID: 5431862
  2. Antimicrobial therapy of experimental endocarditis caused by Staphylococcus aureus.
    J Infect Dis. 1975 Apr;131(4):367-75 PMID: 1117194
  3. Single or combination therapy of staphylococcal endocarditis in intravenous drug abusers.
    Ann Intern Med. 1979 May;90(5):789-91 PMID: 434682
  4. Staphylococcal bacteremia and endocarditis: state of the art.
    Arch Intern Med. 1982 Jun;142(6):1169-77 PMID: 6807232
  5. Community-acquired methicillin-resistant Staphylococcus aureus endocarditis in the Detroit Medical Center.
    Ann Intern Med. 1982 Sep;97(3):330-8 PMID: 7114630
  6. Vancomycin therapy for methicillin-resistant Staphylococcus aureus.
    Ann Intern Med. 1982 Sep;97(3):344-50 PMID: 7114631
  7. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: A prospective study.
    Ann Intern Med. 1982 Oct;97(4):496-503 PMID: 6751182
  8. Staphylococcus aureus endocarditis: clinical manifestations in addicts and nonaddicts.
    Medicine (Baltimore). 1983 May;62(3):170-7 PMID: 6843356
  9. In vitro activity of ciprofloxacin (Bay o 9867).
    Antimicrob Agents Chemother. 1983 Oct;24(4):568-74 PMID: 6228192
  10. Pharmacokinetics and tissue penetration of ciprofloxacin.
    Antimicrob Agents Chemother. 1983 Nov;24(5):784-6 PMID: 6660852
  11. Imipenem therapy of experimental Staphylococcus aureus and Streptococcus faecalis endocarditis.
    J Antimicrob Chemother. 1983 Dec;12 Suppl D:65-78 PMID: 6421794
  12. Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria.
    Antimicrob Agents Chemother. 1984 Mar;25(3):319-26 PMID: 6232895
  13. In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent.
    Antimicrob Agents Chemother. 1984 Mar;25(3):331-5 PMID: 6721464
  14. The in-vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid.
    J Antimicrob Chemother. 1984 Apr;13(4):325-31 PMID: 6233249
  15. In-vitro studies with ciprofloxacin, a new 4-quinolone compound.
    J Antimicrob Chemother. 1984 Apr;13(4):333-46 PMID: 6233250
  16. Efficacy of vancomycin plus rifampin in experimental aortic-valve endocarditis due to methicillin-resistant Staphylococcus aureus: in vitro-in vivo correlations.
    J Infect Dis. 1985 Jan;151(1):157-65 PMID: 3965588
  17. The in-vitro activity of some antimicrobial agents against methicillin-resistant Staphylococcus aureus.
    J Antimicrob Chemother. 1985 Mar;15(3):291-5 PMID: 3158632
  18. Efficacy of imipenem/cilastatin in endocarditis.
    Am J Med. 1985 Jun 7;78(6A):117-21 PMID: 3859210
  19. Efficacy of ciprofloxacin for experimental endocarditis caused by methicillin-susceptible or -resistant strains of Staphylococcus aureus.
    Antimicrob Agents Chemother. 1986 Sep;30(3):382-4 PMID: 3640590
  20. Ciprofloxacin versus vancomycin in the therapy of experimental methicillin-resistant Staphylococcus aureus endocarditis.
    Antimicrob Agents Chemother. 1987 Apr;31(4):527-30 PMID: 3649202
Article Info
Journal
Antimicrobial agents and chemotherapy
Abbr.
Antimicrob Agents Chemother
ISSN
0066-4804
DOI
10.1128/AAC.32.5.747
Published
1988-05-00
Pages
747-51
Language
English
Region
United States
NLM ID
0315061
PMCID
PMC172264
Subset
IM
External Links
PubMed source DOI: 10.1128/AAC.32.5.747 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2